Acute coronary syndrome is a term used for conditions brought on by sudden, reduced blood flow to the heart. Symptoms include chest pain, pain elsewhere in the body, such as the left upper arm or jaw, nausea, vomiting and shortness of breath. Risk factors include age, high blood pressure, high blood cholesterol, cigarette smoking and Type 2 diabetes. Treatment includes beta blockers, calcium channel blockers, cholesterol-lowering drugs and angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBS).
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/146223 .
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Coronary Syndrome – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Coronary Syndrome (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Coronary Syndrome (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Acute Coronary Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 6, 3, 9 and 1 respectively.Acute Coronary Syndrome.
Acute Coronary Syndrome (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Browse the complete report @ http://www.orbisresearch.com/reports/index/acute-coronary-syndrome-pipeline-review-h2-2016 .
Arena Pharmaceuticals, Inc.
Ascendia Pharmaceuticals LLC
Athera Biotechnologies AB
Cardiome Pharma Corp.
Cerenis Therapeutics Holding SA
Esperion Therapeutics, Inc.
Japan Tobacco Inc.
Lee's Pharmaceutical Holdings Limited
LipimetiX Development Inc
The Medicines Company
If you have any enquiry before buying a copy of this report @ http://www.orbisresearch.com/contacts/enquiry-before-buying/146223 .
List of Figures
Number of Products under Development for Pompe Disease, H2 2016 9
Number of Products under Development for Pompe Disease - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Assessment by Monotherapy Products, H2 2016 29
Contact email@example.com for more information.
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas - 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research
Follow us on Twitter: https://twitter.com/orbisresearch
Like us on Facebook: https://www.facebook.com/pages/Orbis-Research/820969017982115